The primary role of the Mouse Genetics Core is to facilitate the use of mouse molecular genetics at MSK for in vivo studies of gene functions germane to cancer. Relevant fields in which MSK investigators develop and apply mouse models include: cell growth and behavior, stem cell biology, embryonic development, immunobiology, genome integrity, cancer biology, and experimental therapeutics. The MGC consists of 2 sections: the Transgenic/Embryology Group (TgG) and the Molecular Biology/Tissue Culture Group (MBTCG). Major services offered by the TgG include the production of genetically engineered mice (GEM) by pronuclear injection of DNA or CRISPR/Cas9 and by blastocyst injection of ES cells; cryopreservation and the long-term storage of GEM lines; strain rederivation or recovery through IVF and/or embryo transfer; performance of special embryological and animal surgical procedures; and the provision of GEM lines such as CRE and FLPe expressing strains. The specialized molecular biology services provided by the MBTCG include transgene DNA purification and genotyping of founder mice; the design and production of CRISPR/Cas9 reagents for mouse genome editing; and the identification and verification of alleles carried by gene edited mice. Services offered by the MBTCG also include performing all aspects of gene targeting in mouse ES cells and establishing ES cells from GEM lines. An integral role of the MGC is to provide consultation and training in the design and production of mouse models, ES cell culture, and mouse husbandry and genetics. Rapid advances in genome editing and sequencing technologies, in combination with the steady increase in translational research at MSK, have resulted in a significant upsurge in demand for MGC services. In addition, the Core continues to pursue and implement new technical developments that will expedite gene editing in mice; ongoing efforts include the use of commercially available synthetic gRNA components and the application of electroporation to deliver CRIPSR/Cas9 into mouse zygotes. Integrating such advancements into the Core?s services will undoubtedly increase the productivity and reduce staff time/effort to create GEM models for MSK investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Meester, Reinier G S; Peterse, Elisabeth F P; Knudsen, Amy B et al. (2018) Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer 124:2974-2985
Kinsella, Netty; Stattin, Pär; Cahill, Declan et al. (2018) Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol 74:261-280
Breitbart, William (2018) Dignity and Meaning in Supportive Care. Palliat Support Care 16:641-642
Casey, E; Bournazos, S; Mo, G et al. (2018) A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32:547-549
Okondo, Marian C; Rao, Sahana D; Taabazuing, Cornelius Y et al. (2018) Inhibition of Dpp8/9 Activates the Nlrp1b Inflammasome. Cell Chem Biol 25:262-267.e5
Gutierrez, Alejandro; Kentsis, Alex (2018) Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. Br J Haematol 180:919-924
Ruff, Emily F; Muretta, Joseph M; Thompson, Andrew R et al. (2018) A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation. Elife 7:
Atkins, Katelyn M; Chen, Ming-Hui; Wu, Jing et al. (2018) Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer 124:1383-1390
Traina, Tiffany A; Miller, Kathy; Yardley, Denise A et al. (2018) Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol 36:884-890
Guo, Jun; Jin, Jie; Oya, Mototsugu et al. (2018) Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol 11:69

Showing the most recent 10 out of 8799 publications